OBJECTIVE: To evaluate early and long term anamnestic response to a booster dose of HBV vaccine among non-seroprotected children. SUBJECTS AND METHOD: A national community based project was carried out on 3600 children aged 9 months to 16 years, fully vaccinated during infancy. They were recruited from 6 governorates representing Egypt. It revealed that 1535 children (42.8%) had non sero-protective anti-HBs (<10 IU/L) and were HBsAg or anti-HBc negative. A challenging dose of 10 μg of mono-valent Euvax HBV vaccine was given to 1121/1535 children. Quantitative assessment of anti-HBs was performed to detect early (2-4 weeks) and long term (one year) anamnestic responses. RESULTS: Early anamnestic response developed among 967/1070 children (90.3%).Children having detectable anti-HBs (1-9 IU/L) significantly developed early anamnestic response (90%) compared to 85% with undetectable anti-HBs (<1 IU/L), P < 0.001. Multiple logistic analysis revealed that undetectable anti-HBs, living in rural residence and children aged 15-16 years were the most significant predicting risk factors for the absence of early anamnestic response (<10 IU/L), with AOR 2.7, 2.7 & 4.7 respectively. After one year, long term anamnestic response was absent among 15% of children who previously showed early response. Poor early anamnestic response and undetectable pre-booster anti-HBs were the significant predicting risk factors for absent long term anamnestic response, with AOR 18.7 & 2.7 respectively. CONCLUSION: Immunological memory for HBV vaccine outlasts the presence of anti- HBs and HBV vaccination program provides effective long term protection even in children showing waning or undetectable concentrations of anti-HBs. This signifies no need for a booster dose especially to healthy children.
OBJECTIVE: To evaluate early and long term anamnestic response to a booster dose of HBV vaccine among non-seroprotected children. SUBJECTS AND METHOD: A national community based project was carried out on 3600 children aged 9 months to 16 years, fully vaccinated during infancy. They were recruited from 6 governorates representing Egypt. It revealed that 1535 children (42.8%) had non sero-protective anti-HBs (<10 IU/L) and were HBsAg or anti-HBc negative. A challenging dose of 10 μg of mono-valent Euvax HBV vaccine was given to 1121/1535 children. Quantitative assessment of anti-HBs was performed to detect early (2-4 weeks) and long term (one year) anamnestic responses. RESULTS: Early anamnestic response developed among 967/1070 children (90.3%).Children having detectable anti-HBs (1-9 IU/L) significantly developed early anamnestic response (90%) compared to 85% with undetectable anti-HBs (<1 IU/L), P < 0.001. Multiple logistic analysis revealed that undetectable anti-HBs, living in rural residence and children aged 15-16 years were the most significant predicting risk factors for the absence of early anamnestic response (<10 IU/L), with AOR 2.7, 2.7 & 4.7 respectively. After one year, long term anamnestic response was absent among 15% of children who previously showed early response. Poor early anamnestic response and undetectable pre-booster anti-HBs were the significant predicting risk factors for absent long term anamnestic response, with AOR 18.7 & 2.7 respectively. CONCLUSION: Immunological memory for HBV vaccine outlasts the presence of anti- HBs and HBV vaccination program provides effective long term protection even in children showing waning or undetectable concentrations of anti-HBs. This signifies no need for a booster dose especially to healthy children.
Authors: Iman Ibrahim Salama; Hala M Raslan; Ghada A Abdel-Latif; Somaia I Salama; Samia M Sami; Fatma A Shaaban; Aida M Abdelmohsen; Walaa A Fouad Journal: World J Hepatol Date: 2022-06-27
Authors: Ammal M Metwally; Dalia M Elmosalami; Hazem Elhariri; Lobna A El Etreby; Ahmed Aboulghate; Marwa M El-Sonbaty; Amira Mohsen; Rehan M Saleh; Ghada A Abdel-Latif; Sahar Samy; Sherif E El Deeb; Asmaa M Fathy; Mohab M Salah; Mohamed A Abdel Mawla; Hanaa M Imam; Nihad A Ibrahim; Fatma A Shaaban; Reham Y Elamir; Mohamed Abdelrahman; Manal H El-Sayed Journal: PLoS One Date: 2021-02-23 Impact factor: 3.240
Authors: H. Yasemin Balaban; Abdullah Tarık Aslan; Şefika Nur Ayar; Osman Dağ; Alpaslan Alp; Cem Şimşek; Cavanşir Vahabov; Tolga Yıldırım; Hakan Göker; Yahya Büyükaşık; Halis Şimşek Journal: Turk J Med Sci Date: 2021-06-28 Impact factor: 0.973
Authors: Ammal M Metwally; Ghada A Abdel-Latif; Lobna Eletreby; Ahmed Aboulghate; Amira Mohsen; Hala A Amer; Rehan M Saleh; Dalia M Elmosalami; Hend I Salama; Safaa I Abd El Hady; Raefa R Alam; Hanan A Mohamed; Hanan M Badran; Hanan E Eltokhy; Hazem Elhariri; Thanaa Rabah; Mohamed Abdelrahman; Nihad A Ibrahim; Nada Chami Journal: BMC Med Ethics Date: 2020-06-15 Impact factor: 2.652